More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Regeneron’s fianlimab lung test approaches
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Regeneron works to secure fianlimab
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
